Clinical Trial Search

Primary: Co-Primary Endpoint 1: Percentage of Participants Who Achieved Clinical Remission as Measured by Partial Mayo Score (PMS) at Week 8 - Induction Period — 43.3; 59.6…

Primary: Total Number of Hypoglycemia Events (Blood Glucose < 60mg/dL) Within 24 Hours of Baseline Visit — 0 events

Primary: Safety Endpoint: The Rate of Major Complications After an Attempted ADO II AS Device Implant — 0; 2.8 percentage of participants

Primary: Idiopathic Pulmonary Fibrosis (IPF)-Related Costs — 38923.57; 22613.68; 20369.94; 37183.17 Euro (€) — p=0.0002

Primary: Percentage Change in LDL-C From Baseline to Day 510 — -56.34; 1.30 percent change — p=<.0001

Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in Part A and Part C — 0; 0; 0 Participants

Primary: Percentage of Patients With Local-regional Control Rate — 100 percentage

Primary: Changes in Brain Activation — 48.5; -30 voxels

Primary: The Primary Efficacy Endpoint is the Number of Subjects Whose Identified Common Warts Are Determined to be Clear on the PWA Scale (PWA=0) at Visit 10 (Day 60) — 33; 8…

Primary: Frequency Counts and Percentage of Subjects With Adverse Events — 6; 6; 1; 3 Participants

Primary: Number of Subjects With an Overall Response (i.e. Either Complete Response or Partial Response) Evaluated at Three Months Post Infusion. — 24; 1; 1 Participants

Primary: Overall Procedure Time — 64.5; 54.1 minutes

Primary: Adverse Response to rTMS — 0; 0 Participants

Primary: Number of Eyes With Epithelial Edema - Slit Lamp Findings — 112; 56; 0; 0 Eyes

Primary: Change From Baseline to Follow-up in Clinician Administered Post-Traumatic Stress Disorder Scale Total Severity Score — -35.59; -44.164; -33.19; -44.95 change in scale…